HER2-Positive Breast Cancer | Data + Perspectives: Clinical Investigators Explore the Current and Future Management of HER2-Positive Breast Cancer

published 3 weeks ago by Dr Neil Love

Proceedings from a satellite symposium during the 42nd annual San Antonio Breast Cancer Symposium. Featuring perspectives from Drs Adam M Brufsky, Lisa A Carey, Sara Hurvitz and Martine J Piccart-Gebhart. Introduction Program Overview: Dr Love (00:00) Considerations in the Care of Patients with Localized HER2-Positive Breast Cancer (BC) Receiving Neoadjuvant Systemic Therapy Case (Dr Brufsky): A woman in her mid-30s with an ER-positive, HER2-positive, node-negative IDC receives neoadjuvant TCHP and at surgery is found to have residual disease in the breast (10:40) Case (Dr Carey): A woman in her mid-80s with a large ER-positive, HER2-positive, node-positive IDC has difficulty tolerating neoadjuvant therapy and has a small amount of residual disease in the breast at surgery (13:10) Faculty Presentation: Dr Carey (16:53) Adjuvant and Extended-Adjuvant Therapy for Patients with Localized HER2-Positive BC Case (Dr Brufsky): A woman in her early 60s with a 1.5-cm, ER-positive, HER2-positive IDC and 3 positive sentinel nodes (30:51) Case (Dr Carey): A woman in her mid-40s with ER-negative, HER2-positive, node-negative BC receives adjuvant T-DM1 on the ATTEMPT trial (36:54) Faculty Presentation: Dr Piccart-Gebhart (42:11) Available Therapeutic Options for the Management of HER2-Positive Metastatic BC (mBC) Case (Dr Hurvitz): A woman in her early 60s with HER2-positive mBC to the liver achieves a complete response to THP → HP but develops CNS metastases 3 years later (52:43) Case (Dr Piccart-Gebhart): A woman in her late 30s with heavily pretreated ER-positive, HER2-positive mBC receives neratinib/letrozole (55:07) Faculty Presentation: Dr Brufsky (57:51) Novel Agents and Strategies Under Evaluation for Patients with HER2-Positive mBC Case (Dr Hurvitz): A woman in her late 40s with ER-positive, HER2-positive mBC receives trastuzumab deruxtecan on a clinical trial after disease progression on multiple lines of therapy (1:09:56) Case (Dr Piccart-Gebhart): A woman in her late 20s receives multiple lines of local and systemic therapy for ER-positive, HER2-positive mBC (1:11:29) Faculty Presentation: Dr Hurvitz (1:13:41) CME information and select publications

more episodes from Research To Practice | Oncology Videos